Project

A 24 week, randomized, double-blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in pulmonary arterial hypertension (PAH)

Aborted · 2012 until 2014

Burger Barbara, Haider Karin, Brutsche Martin